Morgan Stanley’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.8M | Buy |
4,754,188
+708,859
| +18% | +$1.01M | ﹤0.01% | 3800 |
|
|
2025
Q1 | $6.47M | Buy |
4,045,329
+205,860
| +5% | +$329K | ﹤0.01% | 3706 |
|
|
2024
Q4 | $13.8M | Buy |
3,839,469
+1,513,335
| +65% | +$5.45M | ﹤0.01% | 3097 |
|
|
2024
Q3 | $13.3M | Buy |
2,326,134
+1,188,196
| +104% | +$6.77M | ﹤0.01% | 3203 |
|
|
2024
Q2 | $5.26M | Buy |
1,137,938
+623,755
| +121% | +$2.88M | ﹤0.01% | 3831 |
|
|
2024
Q1 | $4.2M | Buy |
514,183
+103,501
| +25% | +$846K | ﹤0.01% | 4043 |
|
|
2023
Q4 | $2.32M | Buy |
410,682
+97,605
| +31% | +$551K | ﹤0.01% | 4839 |
|
|
2023
Q3 | $582K | Buy |
313,077
+72,038
| +30% | +$134K | ﹤0.01% | 5102 |
|
|
2023
Q2 | $663K | Sell |
241,039
-53,099
| -18% | -$146K | ﹤0.01% | 5072 |
|
|
2023
Q1 | $924K | Sell |
294,138
-85,061
| -22% | -$267K | ﹤0.01% | 4907 |
|
|
2022
Q4 | $2.24M | Buy |
379,199
+34,812
| +10% | +$205K | ﹤0.01% | 4380 |
|
|
2022
Q3 | $3.02M | Sell |
344,387
-111,069
| -24% | -$974K | ﹤0.01% | 4109 |
|
|
2022
Q2 | $3.43M | Sell |
455,456
-202,116
| -31% | -$1.52M | ﹤0.01% | 4098 |
|
|
2022
Q1 | $16M | Sell |
657,572
-260,898
| -28% | -$6.33M | ﹤0.01% | 2366 |
|
|
2021
Q4 | $29.6M | Buy |
918,470
+628,374
| +217% | +$20.2M | ﹤0.01% | 1754 |
|
|
2021
Q3 | $13M | Buy |
290,096
+13,908
| +5% | +$621K | ﹤0.01% | 2587 |
|
|
2021
Q2 | $10.5M | Buy |
276,188
+254,993
| +1,203% | +$9.65M | ﹤0.01% | 2923 |
|
|
2021
Q1 | $784K | Buy |
21,195
+12,087
| +133% | +$447K | ﹤0.01% | 4879 |
|
|
2020
Q4 | $302K | Buy |
+9,108
| New | +$302K | ﹤0.01% | 5368 |
|